Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer

References

• FisherBJeongJHBryantJNational Surgical Adjuvant Breast and Bowel Project randomised clinical trialsTreatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trialsLancet2004364943785886815351193
   PubMed Web of Science ®Google Scholar
• GaleaMHBlameyRWElstonCEEllisIOThe Nottingham Prognostic Index in primary breast cancerBreast Cancer Res Treat19922232072191391987
   PubMed Web of Science ®Google Scholar
• OakmanCBessiSZafaranaEGalardiFBiganzoliLDi LeoARecent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancerBreast Cancer Res200911220519435470
   PubMed Web of Science ®Google Scholar
• FoulkesWDSize surprise? Tumour size, nodal status, and outcome after breast cancerCurr Oncol201219524124323144568
   PubMed Web of Science ®Google Scholar
• SorlieTPerouCMTibshiraniRGene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProc Natl Acad Sci U S A20019819108691087411553815
   PubMed Web of Science ®Google Scholar
• BlowsFMDriverKESchmidtMKSubtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studiesPLoS Med201075e100027920520800
   PubMed Web of Science ®Google Scholar
• GoldhirschAWoodWCCoatesASGelberRDThürlimannBSennHJPanel membersStrategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Ann Oncol20112281736174721709140
   PubMed Web of Science ®Google Scholar
• McVeighTPAl-AzawiDKearneyDEAssessing the impact of neoadjuvant chemotherapy on the management of the breast and axilla in breast cancerClin Breast Cancer2014141202524157259
   PubMed Web of Science ®Google Scholar
• BougheyJCMcCallLMBallmanKVTumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical TrialAnn Surg20142604608614 discussion 614–61625203877
   PubMed Web of Science ®Google Scholar
• LippmanMEAllegraJCThompsonEBThe relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancerN Engl J Med19782982212231228651963
   PubMed Web of Science ®Google Scholar
• CroninMSangliCLiuMLAnalytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancerClin Chem20075361084109117463177
   PubMed Web of Science ®Google Scholar
• SparanoJAPaikSDevelopment of the 21-gene assay and its application in clinical practice and clinical trialsJ Clin Oncol200826572172818258979
   PubMed Web of Science ®Google Scholar
• PaikSShakSTangGA multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancerN Engl J Med2004351272817282615591335
   PubMed Web of Science ®Google Scholar
• HabelLAShakSJacobsMKA population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patientsBreast Cancer Res200683R2516737553
   PubMed Web of Science ®Google Scholar
• PaikSTangGShakSGene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancerJ Clin Oncol200624233726373416720680
   PubMed Web of Science ®Google Scholar
• TangGShakSPaikSComparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20Breast Cancer Res Treat2011127113314221221771
   PubMed Web of Science ®Google Scholar
• SgroiDCSestakICuzickJPrediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study populationLancet Oncol201314111067107624035531
   PubMed Web of Science ®Google Scholar
• SestakICuzickJDowsettMPrediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence scoreJ Clin Oncol201533891692225332252
   PubMed Web of Science ®Google Scholar
• SestakIDowsettMZabagloLFactors predicting late recurrence for estrogen receptor-positive breast cancerJ Natl Cancer Inst2013105191504151124029245
   PubMedGoogle Scholar
• SparanoJAGrayRJMakowerDFProspective validation of a 21-gene expression assay in breast cancerN Engl J Med2015373212005201426412349
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)PetoRDaviesCGodwinJComparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trialsLancet2012379981443244422152853
   PubMed Web of Science ®Google Scholar
• NICEGene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat NICE Diagnostics guidance [DG10]2013 Available from: https://www.nice.org.uk/guidance/dg10Accessed March 1, 2017
   Google Scholar
• NCCN.orgNational Comprehensive Cancer Network (NCCN) Clinical Practic Guidelines in Oncology -Breast Cancer (Version 2.2016)2016 Available from: http://www.nccn.org/professionals/physicians_gls/pdf/breast.pdfAccessed March 1, 2017
   Google Scholar
• SenkusEKyriakidesSOhnoSESMO Guidelines CommitteePrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201526Suppl 5v8v3026314782
   PubMed Web of Science ®Google Scholar
• DinanMAMiXReedSDHirschBRLymanGHCurtisLHInitial Trends in the use of the 21-gene recurrence score assay for patients with breast cancer in the medicare population, 2005–2009JAMA Oncol20151215816626181015
   PubMed Web of Science ®Google Scholar
• McVeighTPHughesLMMillerNThe impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centreEur J Cancer201450162763277025240289
   PubMed Web of Science ®Google Scholar
• JasemJAminiARabinovitchR21-Gene recurrence score assay as a predictor of adjuvant chemotherapy administration for early-stage breast cancer: an analysis of use, therapeutic implications, and disparity profileJ Clin Oncol201634171995200227001563
   PubMed Web of Science ®Google Scholar
• HenryLRStojadinovicASwainSMPrindivilleSCordesRSoballePWThe influence of a gene expression profile on breast cancer decisionsJ Surg Oncol200999631932319204954
   PubMed Web of Science ®Google Scholar
• LoSSMumbyPBNortonJProspective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selectionJ Clin Oncol201028101671167620065191
   PubMed Web of Science ®Google Scholar
• AsadJJacobsonAFEstabrookADoes oncotype DX recurrence score affect the management of patients with early-stage breast cancer?Am J Surg2008196452752918809056
   PubMed Web of Science ®Google Scholar
• LoncasterJArmstrongAHowellSImpact of oncotype DX breast recurrence score testing on adjuvant chemotherapy use in early breast cancer: real world experience in greater Manchester, UKEur J Surg Oncol Epub201719
   Web of Science ®Google Scholar
• RutterCEYaoXManciniBRInfluence of a 21-gene recurrence score assay on chemotherapy delivery in breast cancerClin Breast Cancer2016161596226483315
   PubMed Web of Science ®Google Scholar
• BaehnerFSangliCMillwardCCherbavazDGoddardAShakSQuantitative gene expression analysis using Oncotype DX in ductal carcinoma in situ that is adjacent to invasive ductal carcinomaCancer Res200969Suppl 22066
   Web of Science ®Google Scholar
• SolinLJGrayRBaehnerFLA multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breastJ Natl Cancer Inst20131051070171023641039
   PubMed Web of Science ®Google Scholar
• SparanoJATAILORx: trial Assigning Individualized Options for Treatment (Rx)Clin Breast Cancer20067434735017092406
   PubMed Web of Science ®Google Scholar
• WenHYKrystel-WhittemoreM2PatilSBreast carcinoma with an Oncotype Dx recurrence score <18: rate of distant metastases in a large series with clinical follow-upCancer2017123113113727526056
   PubMed Web of Science ®Google Scholar
• AlbanellJSvedmanC2GligorovJPooled analysis of prospective European studies assessing the impact of using the 21-gene recurrence score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancerEur J Cancer20166610411327544930
   PubMed Web of Science ®Google Scholar
• BerryDACirrincioneCHendersonICEstrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancerJAMA2006295141658166716609087
   PubMed Web of Science ®Google Scholar
• AlbainKSBarlowWERavdinPMBreast Cancer Intergroup of North AmericaAdjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trialLancet200937497072055206320004966
   PubMed Web of Science ®Google Scholar
• AlbainKSBarlowWEShakSBreast Cancer Intergroup of North AmericaPrognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialLancet Oncol2010111556520005174
   PubMed Web of Science ®Google Scholar
• DowsettMCuzickJWaleCPrediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC studyJ Clin Oncol201028111829183420212256
   PubMed Web of Science ®Google Scholar
• GoldsteinLJGrayRBadveSPrognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic featuresJ Clin Oncol200826254063407118678838
   PubMed Web of Science ®Google Scholar
• MamounasETangGPaikSPrognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: results from NSABP B-28J Clin Oncol201230Suppl 27 Abstract 1
   Web of Science ®Google Scholar
• SunZPratACheangMCGelberRDPerouCMChemotherapy benefit for ‘ER-positive’ breast cancer and contamination of nonluminal subtypes-Waiting for TAILORx and RxPONDERAnn Oncol2015261707425355719
   PubMed Web of Science ®Google Scholar
• Bargallo-RochaJELara-MedinaFPérez-SánchezVCost-effectiveness of the 21-gene breast cancer assay in MexicoAdv Ther201532323925325740550
   PubMed Web of Science ®Google Scholar
• SmythLWatsonG2WalshEMEconomic impact of 21-gene recurrence score testing on early-stage breast cancer in IrelandBreast Cancer Res Treat2015153357358226364296
   PubMed Web of Science ®Google Scholar
• KipMMontebanHSteutenLLong-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspectiveJ Comp Eff Res20154543344525872415
   PubMed Web of Science ®Google Scholar
• HallPSMcCabeCSteinRCCameronDEconomic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancerJ Natl Cancer Inst20121041566622138097
   PubMedGoogle Scholar
• BrufskyAMPredictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancerAm J Clin Oncol201437440441024853663
   PubMed Web of Science ®Google Scholar
• KarstenMStempelMRadosaJPatilSKingTAOncotype DX in bilateral synchronous primary invasive breast cancerAnn Surg Oncol201623247147626340863
   PubMed Web of Science ®Google Scholar
• AlexandrovLBNik-ZainalSWedgeDCSignatures of mutational processes in human cancerNature2013500746341542123945592
   PubMed Web of Science ®Google Scholar
• Nik-ZainalSDaviesH1StaafJLandscape of somatic mutations in 560 breast cancer whole-genome sequencesNature20165347605475427135926
   PubMed Web of Science ®Google Scholar
• ArunBBayraktarSLiuDDResponse to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experienceJ Clin Oncol201129283739374621900106
   PubMed Web of Science ®Google Scholar
• NarodSAMetcalfeKLynchHTShould all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?Breast Cancer Res Treat2013138127327923381743
   PubMed Web of Science ®Google Scholar
• FoulkesWDStefanssonIMChappuisPOGermline BRCA1 mutations and a basal epithelial phenotype in breast cancerJ Natl Cancer Inst200395191482148514519755
   PubMedGoogle Scholar
• LakhaniSRVan De VijverMJJacquemierJThe pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2J Clin Oncol20022092310231811981002
   PubMed Web of Science ®Google Scholar
• ShahPDPatilSDicklerMNOffitKHudisCARobsonMETwenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: differences based on germline mutation statusCancer201612281178118426859126
   PubMed Web of Science ®Google Scholar
• LewinRSulkesAShochatTOncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutationsBreast Cancer Res Treat2016157351151627225387
   PubMed Web of Science ®Google Scholar
• WeldonCBTrosmanJRGradisharWJBensonAB3rdSchinkJCBarriers to the use of personalized medicine in breast cancerJ Oncol Pract201284e24e3123180995
   PubMedGoogle Scholar
• RobertsMCBrysonAWeinbergerMOncologists’ barriers and facilitators for Oncotype Dx use: qualitative studyInt J Technol Assess Health Care201632535536127958190
   PubMed Web of Science ®Google Scholar
• BombardYRozmovitsLTrudeauMLeighlNBDealKMarshallDAThe value of personalizing medicine: medical oncologists’ views on gene expression profiling in breast cancer treatmentOncologist201520435135625746345
   PubMed Web of Science ®Google Scholar
• LeggettLELorenzettiDLNoseworthyTTiwanaSMackeanGClementFExperiences and attitudes toward risk of recurrence testing in women with breast cancer: a systematic reviewBreast Cancer Res Treat2014144345746524596049
   PubMed Web of Science ®Google Scholar
• TzengJPMayerDRichmanARWomen’s experiences with genomic testing for breast cancer recurrence riskCancer201011681992200020213682
   PubMed Web of Science ®Google Scholar
• O’NeillSCBrewerNTLillieSEWomen’s interest in gene expression analysis for breast cancer recurrence riskJ Clin Oncol200725294628463417925559
   PubMed Web of Science ®Google Scholar